Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Receivables (2017 - 2023)

VYNE Therapeutics (VYNE) has disclosed Change in Receivables for 5 consecutive years, with $16000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Receivables fell 90.42% year-over-year to $16000.0, compared with a TTM value of $244000.0 through Sep 2023, up 102.7%, and an annual FY2018 reading of -$786000.0, down 200.0% over the prior year.
  • Change in Receivables was $16000.0 for Q3 2023 at VYNE Therapeutics, down from $129000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $798000.0 in Q2 2021 and bottomed at -$8.0 million in Q1 2022.
  • Average Change in Receivables over 3 years is -$1.5 million, with a median of -$68000.0 recorded in 2023.
  • The sharpest move saw Change in Receivables crashed 128.95% in 2022, then skyrocketed 155.84% in 2023.
  • Year by year, Change in Receivables stood at -$996000.0 in 2021, then soared by 116.77% to $167000.0 in 2022, then tumbled by 90.42% to $16000.0 in 2023.
  • Business Quant data shows Change in Receivables for VYNE at $16000.0 in Q3 2023, $129000.0 in Q2 2023, and -$68000.0 in Q1 2023.